{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:37:35Z","timestamp":1788795455149,"version":"build-2803163510"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["18ZR1431200"],"award-info":[{"award-number":["18ZR1431200"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007279","name":"Shanghai Municipal Health Bureau","doi-asserted-by":"publisher","award":["20194Y0112"],"award-info":[{"award-number":["20194Y0112"]}],"id":[{"id":"10.13039\/501100007279","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014137","name":"Shanghai Shenkang Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2020CR4089"],"award-info":[{"award-number":["SHDC2020CR4089"]}],"id":[{"id":"10.13039\/501100014137","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Zellweger spectrum disorder (ZSD) is a heterogeneous group of autosomal recessive disorders characterized by a defect in peroxisome formation and attributable to mutations in the <jats:italic>PEX<\/jats:italic> gene family. Patients with ZSD have profound neurologic impairments, including seizures, severe retardation, and dysmorphic features, and poor prognosis. Currently, there is no specific, effective treatment. Here, we investigated the effects of allogeneic hematopoietic stem cell transplantation (allo-HSCT) on <jats:italic>PEX1<\/jats:italic>-related ZSD. The suspected clinical proband was first diagnosed at the Department of Neurology of our hospital. The proband died soon after diagnosis, and his family was studied. We found that a brother had the same genetic alterations, and he was diagnosed with Infantile Refsum disease (IRD) as the mildest form of ZSD. We implemented treatment with allo-HSCT, at the request of the child's parents. After transplantation, we observed significant improvements in the clinical manifestations, very-long-chain fatty acids, and brain MRI. The patient has recovered well and not showed any abnormal clinical manifestations after 2 years of follow-up. We have achieved satisfactory short-term results in the treatment of ZSD-IRD with allo-HSCT. Long-term follow-up and observation will be performed to determine the long-term prognosis.<\/jats:p>","DOI":"10.3389\/fped.2021.672187","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T11:23:51Z","timestamp":1629890631000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Allogeneic Hematopoietic Stem Cell Transplantation for PEX1-Related Zellweger Spectrum Disorder: A Case Report and Literature Review"],"prefix":"10.3389","volume":"9","author":[{"given":"Kai","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Bo","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ming","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu-Hen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"key":"B1","article-title":"Zellweger Spectrum Disorder","author":"Steinberg","year":"2003"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.bbamcr.2006.09.010","article-title":"Peroxisome biogenesis disorders","volume":"1763","author":"Steinberg","year":"2006","journal-title":"Biochim Biophys Acta."},{"key":"B3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ymgme.2015.12.009","article-title":"Peroxisome biogenesis disorders in the Zellweger spectrum: an overview of current diagnosis, clinical manifestations, and treatment guidelines","volume":"117","author":"Braverman","year":"2016","journal-title":"Mol Genet Metab."},{"key":"B4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10545-015-9880-2","article-title":"Zellweger spectrum disorders: clinical manifestations in patients surviving into adulthood","volume":"39","author":"Berendse","year":"2016","journal-title":"J Inherit Metab Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13023-015-0368-9","article-title":"Zellweger spectrum disorders: clinical overview and management approach","volume":"10","author":"Klouwer","year":"2015","journal-title":"Orphanet J Rare Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e180769","DOI":"10.1001\/jamanetworkopen.2018.0769","article-title":"Potential risks to stable long-term outcome of allogeneic hematopoietic stem cell transplantation for children with cerebral X-linked adrenoleukodystrophy","volume":"1","author":"Kuhl","year":"2018","journal-title":"JAMA Netw Open."},{"key":"B7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1399-0004.2004.00329.x","article-title":"Peroxisomal disorders I: biochemistry and genetics of peroxisome biogenesis disorders","volume":"67","author":"Wanders","year":"2005","journal-title":"Clin Genet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0378-4347(98)00186-8","article-title":"Rapid stable isotope dilution analysis of very-long-chain fatty acids, pristanic acid and phytanic acid using gas chromatography-electron impact mass spectrometry","volume":"713","author":"Vreken","year":"1998","journal-title":"J Chromatogr B Biomed Sci Appl."},{"key":"B9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/jb\/mvy085","article-title":"Application of machine learning algorithms for the differential diagnosis of peroxisomal disorders","volume":"165","author":"Subhashini","year":"2019","journal-title":"J Biochem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.sjopt.2017.09.004","article-title":"A clinical case of Zellweger syndrome in a patient with a previous history of ocular medulloepithelioma","volume":"32","author":"Galvez-Ruiz","year":"2018","journal-title":"Saudi J Ophthalmol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1159\/000490095","article-title":"Long-term cholic acid therapy in zellweger spectrum disorders","volume":"12","author":"Heubi","year":"2018","journal-title":"Case Rep Gastroenterol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/0887-8994(95)00215-4","article-title":"MRI findings of Zellweger syndrome","volume":"13","author":"Nakai","year":"1995","journal-title":"Pediatr Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13256-017-1365-5","article-title":"Identification of a novel mutation in PEX10 in a patient with attenuated Zellweger spectrum disorder: a case report","volume":"11","author":"Blomqvist","year":"2017","journal-title":"J Med Case Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1182\/blood-2011-01-329235","article-title":"Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report","volume":"118","author":"Miller","year":"2011","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1182\/blood-2003-10-3402","article-title":"Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999","volume":"104","author":"Peters","year":"2004","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S0140-6736(00)02629-5","article-title":"Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy","volume":"356","author":"Shapiro","year":"2000","journal-title":"Lancet"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.672187\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T11:23:54Z","timestamp":1629890634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.672187\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":17,"alternative-id":["10.3389\/fped.2021.672187"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.672187","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,25]]},"article-number":"672187"}}